Phase III Data Confirm Sustained Efficacy, Long-term Safety of Remibrutinib in CSU; Novartis Prepares to File for Approval
Remibrutinib (Novartis) shows sustained efficacy and long-term safety in chronic spontaneous urticaria (CSU), according to data from two Phase III studies. Remibrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor being studied in chronic spontaneous urticaria (CSU) and other immune-mediated conditions such as hidradenitis suppurativa. Novartis will submit remibrutinib for approval in CSU to […]